title: Influence of renal failure on ciprofloxacin pharmacokinetics in rats.
abstract: Ciprofloxacin pharmacokinetics have been shown to be modified in patients with renal failure (e.g., the intestinal secretion of ciprofloxacin is increased). This study investigated the influence of renal failure on the pharmacokinetics of ciprofloxacin following oral and parenteral administration to rats of a dose of 50 mg/kg of body weight. After parenteral administration, only renal clearance (CLR) was reduced in nephrectomized rats (5.3+/-1.4 versus 17.8+/-4.7 ml/min/kg, P < 0.01, nephrectomized versus control rats). However, nonrenal clearance was increased in nephrectomized rats (32+/-4 versus 15+/-5 ml/min/kg, P < 0.01, nephrectomized versus control rats), suggesting compensatory mechanisms for reduced renal function. After oral administration, apparent total clearance and CLR were reduced (P < 0.01) in nephrectomized rats (117+/-25 and 6.8+/-4.4 ml/min/kg, respectively) compared with the values for control rats (185+/-9 and 22.6+/-5.3 ml/min/kg, respectively) and the area under the concentration-time curve was higher (P < 0.01) for nephrectomized rats (436.3+/-90.5 mg. min/liter) than for control rats (271.3+/-14.3 mg.min/liter). Terminal elimination half lives in the two groups remained constant after oral and parenteral administration. These results suggest an increased bioavailability of ciprofloxacin in nephrectomized rats, which was confirmed by a nonlinear mixed-effect model.
authors.affiliation: Service de Pharmacie Clinique et des Biomatériaux, G. H. Bichat-C. Bernard, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Nouaille-Degorce
authors.forename: C
authors.initials: C
authors.lastname: Veau
authors.forename: S
authors.initials: S
authors.lastname: Dautrey
authors.forename: M
authors.initials: M
authors.lastname: Tod
authors.forename: D
authors.initials: D
authors.lastname: Laouari
authors.forename: C
authors.initials: C
authors.lastname: Carbon
authors.forename: R
authors.initials: R
authors.lastname: Farinotti
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D007263:Infusions, Parenteral; D007668:Kidney / Q000187:drug effects* / Q000601:surgery; D008297:Male; D008657:Metabolic Clearance Rate; D009392:Nephrectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D051437:Renal Insufficiency / Q000378:metabolism*
chemical_list: D000890:Anti-Infective Agents; D002939:Ciprofloxacin